The incidence and clinical features of PEGylated filgrastim-induced acute aortitis in patients with breast cancer

[1]  L. Pirilä,et al.  Granulocyte colony-stimulating factor- and chemotherapy-induced large-vessel vasculitis: six patient cases and a systematic literature review , 2020, Rheumatology advances in practice.

[2]  S. Kubo,et al.  Aortitis which developed after the administration of granulocyte-colony stimulating factor , 2020, Modern rheumatology case reports.

[3]  H. Takei,et al.  Granulocyte-colony stimulating factor-associated aortitis in a woman with advanced breast cancer: a case report and review of the literature , 2019, BMC Cancer.

[4]  S. Hirata,et al.  Large-vessel vasculitis associated with PEGylated granulocyte-colony stimulating factor. , 2019, The Netherlands journal of medicine.

[5]  Satoshi Takahashi,et al.  Granulocyte colony-stimulating factor-associated aortitis in the Japanese Adverse Drug Event Report database. , 2019, Cytokine.

[6]  O. Wiklander,et al.  G-CSF-induced aortitis: Two cases and review of the literature. , 2019, Autoimmunity reviews.

[7]  M. Kurokawa,et al.  Arteritis after administration of granulocyte colony-stimulating factor: a case series , 2019, International journal of hematology.

[8]  T. Kurita,et al.  Acute arteritis after G-CSF administration , 2019, International Cancer Conference Journal.

[9]  Ken-ichi Ito,et al.  [A Case of Arteritis That Developed after Pegfilgrastim Administration during Chemotherapy for Breast Cancer]. , 2018, Gan to kagaku ryoho. Cancer & chemotherapy.

[10]  Y. Terao,et al.  Drug-induced aortitis in a patient with ovarian cancer treated with bevacizumab combination therapy. , 2018, Taiwanese journal of obstetrics & gynecology.

[11]  S. Christopher Jones,et al.  Granulocyte colony‐stimulating factors and aortitis: A rare adverse event , 2018, American journal of hematology.

[12]  S. Kaji,et al.  Thoracic aortitis and aortic dissection following pegfilgrastim administration. , 2017, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[13]  E. B. Miller,et al.  Isolated abdominal aortitis following administration of granulocyte colony stimulating factor (G-CSF) , 2016, Clinical Rheumatology.

[14]  Thomas J. Smith,et al.  Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Cluzel,et al.  Th1 and Th17 Cytokines Drive Inflammation in Takayasu Arteritis , 2015, Arthritis & rheumatology.

[16]  Y. Okada,et al.  Adventitial CXCL1/G-CSF Expression in Response to Acute Aortic Dissection Triggers Local Neutrophil Recruitment and Activation Leading to Aortic Rupture , 2015, Circulation research.

[17]  S. Gooding,et al.  Gemcitabine-induced large vessel vasculitis demonstrated by PET CT: a rare, important side effect , 2014, International Journal of Hematology.

[18]  Y. Weerakkody.  Aortitis , 2013, Radiopaedia.org.

[19]  M. Ansari,et al.  Drug-induced Vasculitis in a Breast Cancer Patient Receiving Chemotherapy , 2013 .

[20]  P. Schuetz,et al.  Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future , 2011, BMC medicine.

[21]  C. Hamilton,et al.  Gemcitabine-associated large vessel vasculitis presenting as fever of unknown origin. , 2010, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[22]  N. Kearney,et al.  EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. , 2006, European journal of cancer.

[23]  J. Blohmer,et al.  Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer , 2006, British Journal of Cancer.

[24]  B. Wiens,et al.  First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  C. Darie,et al.  Aortite après injections de G-CSF , 2004 .

[26]  Barbara L. Smith,et al.  Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  D. Link,et al.  G-CSF is an essential regulator of neutrophil trafficking from the bone marrow to the blood. , 2002, Immunity.

[28]  R. Cuchacovich.  Immunopathogenesis of vasculitis , 2002, Current rheumatology reports.

[29]  L. R. Hill,et al.  Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  T. Ulich,et al.  A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. , 1999, Experimental hematology.

[31]  T. Uchida,et al.  Acute arterial thrombosis due to platelet aggregation in a patient receiving granulocyte colony‐stimulating factor , 1996, British journal of haematology.

[32]  H. Scher,et al.  Acute arterial thrombosis after escalated‐dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony‐stimulating factor: A possible new recombinant granulocyte colony‐stimulating factor toxicity , 1992, Cancer.

[33]  C. Flowers,et al.  Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  S. Madajewicz,et al.  Abdominal Aortitis after Use of Granulocyte Colony-Stimulating Factor , 2009, Clinical drug investigation.